Cargando…

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activated prodrug evofosfamide (TH-302) in HNSCC, we established t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harms, Julia K., Lee, Tet-Woo, Wang, Tao, Lai, Amy, Kee, Dennis, Chaplin, John M., McIvor, Nick P., Hunter, Francis W., Macann, Andrew M. J., Wilson, William R., Jamieson, Stephen M.F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678517/ https://www.ncbi.nlm.nih.gov/pubmed/31337055 http://dx.doi.org/10.3390/cells8070717

Ejemplares similares

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
por: Jamieson, Stephen M.F., et al.
Publicado: (2023)

Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer
por: Lee, Tet Woo, et al.
Publicado: (2020)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
por: Brenner, Andrew J., et al.
Publicado: (2021)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models
por: Huizing, Fokko J., et al.
Publicado: (2018)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

(18)F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
por: Grkovski, Milan, et al.
Publicado: (2018)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma
por: Jardim-Perassi, Bruna V., et al.
Publicado: (2021)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck
por: Welsh, Liam, et al.
Publicado: (2017)

Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts
por: Liu, J, et al.
Publicado: (2007)

Hypoxia in Head and Neck Squamous Cell Carcinoma
por: Li, John Zenghong, et al.
Publicado: (2012)

Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.
por: KjellÃ©n, E., et al.
Publicado: (1989)

Electrochemotherapy of radioresistant head and neck squamous cell carcinoma cells and tumor xenografts
por: Zakelj, Martina Niksic, et al.
Publicado: (2019)

Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia
por: Collingridge, D R, et al.
Publicado: (2001)

Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties
por: Makita, Haruna, et al.
Publicado: (2021)

Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer
por: Shaw, R J, et al.
Publicado: (2009)

Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations
por: Bailleul, Quentin, et al.
Publicado: (2021)

The evolving role of tiotropium in asthma
por: McIvor, Emma R, et al.
Publicado: (2017)

Bioactive sphingolipid profile in a xenograft mouse model of head and neck squamous cell carcinoma
por: Bai, Aiping, et al.
Publicado: (2019)

Tumour-infiltrating lymphocytes in the risk stratification of squamous cell carcinoma of the head and neck
por: Jones, T M
Publicado: (2014)

Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma
por: Hill, Rhianna M., et al.
Publicado: (2022)

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide
por: Lüpfert, Christian, et al.
Publicado: (2018)

Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts.
por: Stanton, P., et al.
Publicado: (1994)

Xenograft models of head and neck cancers
por: Sano, Daisuke, et al.
Publicado: (2009)

Establishment and Use of Patient-Derived Xenograft Models for Drug Testing in Head and Neck Squamous Cell Carcinoma
por: Karamboulas, Christina, et al.
Publicado: (2020)

Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib
por: Hu, Fangling, et al.
Publicado: (2021)

The response to chemotherapy of a variety of human tumour xenografts.
por: Steel, G. G., et al.
Publicado: (1983)

The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion.
por: Parkins, C. S., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_1fotte8nmbme4q0c0q7oe9rckl